Data Foundry

Medical device recalls 2014

ADVIA Centaur¿¿ Systems HBc Total — Class II medical device recall Z-0103-2015

Terminated recall by Siemens Healthcare Diagnostics, Inc, reported 2014-10-29, distributed nationwide. Increased imprecision and positive bias is observed with patient samples and negative controls and can result

Recall numberZ-0103-2015
Product typeMedical device
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmSiemens Healthcare Diagnostics, Inc, East Walpole, MA, United States
Recall initiated2014-09-15
Classified2014-10-21
Reported by FDA2014-10-29
Terminated2015-12-28
DistributedNationwide (US)
Countries outside the USAT, BE, BH, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IQ, IT, JO, LB, LT, LU, LV, NL, NO, PL, PT, RO, SE, SK, TR
Quantity5,434
Lot numbers36217064, 36281064, 36449064, 37406064, 38177064
Model numbers07566733
Expiration dates2015-02-10

Product

ADVIA Centaur¿¿ Systems HBc Total (HBcT) Kit. For In Vitro Diagnostic Use. Catalog Number: 07566733 Siemens Material Number: 10309508 The ADVIA Centaur HBc Total assay is an in vitro diagnostic test for the qualitative determination of total antibodies to the core antigen of the hepatitis B virus (HBc Total) in human serum or plasma (potassium EDT A, or lithium or sodium heparinized) using the ADVIA Centaur CP system.

Reason for recall

Increased imprecision and positive bias is observed with patient samples and negative controls and can result in an increase in initial reactive results.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-0103-2015. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.